Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026

뉴스 본문을 불러오고 있어요.

Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026 | 웨이프 WAPE

Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026

기사 요약

관련 종목

댓글 —